Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.94 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL3775695 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL6692875 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL372244 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL6692872 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL5163322 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL25212993 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL8440714 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL260176 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL20917176 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 | |
| Citric Acid SCHEMBL372534 | 1.00 | CA4 (0.94) | CA4CASP1FFAR3HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119082536-A | Preparation process of aluminum alloy material for sports equipment | 海安宏宇合金材料有限公司 | 2024-12-06 | — | — | CN | claimed |
| CN-117822013-A | Cobalt phosphate/electron-rich gold/bismuth vanadate photo-anode and preparation method and application thereof | 武汉纺织大学 | 2024-04-05 | — | — | CN | claimed |
| CN-115926580-B | Light curtain wall aluminum plate and preparation method thereof | 江苏恒美幕墙材料有限公司 | 2024-03-19 | — | — | CN | claimed |
| WO-2024017940-A1 | REPARIXIN LIQUID SUSPENSIONS | DOMPE' FARMACEUTICI SPA (IT) | 2024-01-25 | — | — | WO | claimed |
| EP-4309641-A1 | REPARIXIN LIQUID SUSPENSIONS | Dompe' Farmaceutici S.P.A. (IT) | 2024-01-24 | — | — | EP | claimed |
| WO-2023066251-A1 | CONJUGATE DRUG PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | 同宜医药（苏州）有限公司 | 2023-04-27 | — | — | WO | claimed |
| CN-114276675-A | Nylon 12 composite material for MJR3D printing and preparation method thereof | 福州大学 | 2022-04-05 | — | — | CN | claimed |
| CN-110146603-B | Analysis method for determining release degree of oxcarbazepine sustained-release tablets | 南通联亚药业有限公司 | 2021-11-02 | — | — | CN | claimed |
| CN-109850932-B | Monodisperse Cu with adjustable particle size2O single crystal solid sphere and preparation method thereof | 大连理工大学 | 2020-04-14 | — | — | CN | claimed |
| US-20190216814-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2019-07-18 | — | — | US | claimed |
| CN-100346784-C | pharmaceutical formulations of antineoplastic agents, in particular temozolomide, preparation method and use thereof | SCHERING CORP (US) | 2007-11-07 | — | — | CN | claimed |
| EP-1838307-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2007-10-03 | — | — | EP | claimed |
| WO-2006060464-A1 | METHODS OF USING TEMOZOLOMIDE FORMULATION INTRATHECALLY IN THE TREATMENT OF CANCERS | SCHERING CORPORATION (US) | 2006-06-08 | — | — | WO | claimed |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | SCHERING CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-6987108-B2 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION (US) | 2006-01-17 | — | — | US | claimed |
| WO-2005097124-A1 | LIQUID DOSAGE FORMULATIONS OF DONEPEZIL | EISAI CO., LTD. (JP) | 2005-10-20 | — | — | WO | claimed |
| CN-1635871-A | pharmaceutical formulations of antineoplastic agents, in particular temozolomide, preparation method and use thereof | SCHERING CORP (US) | 2005-07-06 | — | — | CN | claimed |
| EP-1478339-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2004-11-24 | — | — | EP | claimed |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | SCHERING CORPORATION | 2004-03-04 | — | — | US | claimed |
| WO-2003072082-A1 | PHARMACEUTICAL FORMULATIONS OF ANTINEOPLASTIC AGENTS, IN PARTICULAR TEMOZOLOMIDE, PROCESSES OF MAKING AND USING THE SAME | SCHERING CORPORATION (US) | 2003-09-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216814-A1 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE | IL5, IL1A, RRP15 | CA4 4402/4885CASP1 173/4885FFAR3 521/4885 |
| US-20040043001-A1 | Pharmaceutical formulations of antineoplastic agents and processes of making and using the same | ASNS, TP53, QPCTL | CA4 2466/4885CASP1 2019/4885FFAR3 3846/4885 |
| US-20060122162-A1 | Methods of using temozolomide formulation intrathecally in the treatment of cancers | PMP22, TUBB2A, TUBB6 | CA4 678/4885CASP1 1774/4885FFAR3 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.